The Journal of Tehran University Heart Center and with fewer side effects. Atrial selective antiarrhythmic drugs, new class III antiarrhythmics, and new anticoagulants are most mentionable amongst these drugs. References 1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001;285:2370-2375. 2. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D>Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Portugueseirculation 2004;110:1042-1046. 3. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-125. 4. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. JAMA 1994;271:840-844. 5. Conen D, Osswald S, Albert CM. Epidemiology of atrial fibrillation. Swiss Med Wkly 2009;139:346-352. 6. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 2010;375:1212-1223. 7. Bajpai A, Rowland E. Atrial fibrillation. CEACCP 2006;6:219- 224. 8. Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-292. 9. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythmia Electrophysiol 2008;1:62-73. 10. Tanaka K, Zlochiver S, Vikstrom KL, Yamazaki M, Moreno J, Klos M, Zaitsev AV, Vaidyanathan R, Auerbach DS, Landas S, Guiraudon G, Jalife J, Berenfeld O, Kalifa J. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ Res 2007;101:839-847. 11. Duytschaever M, Blaauw Y, Allessie M. Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs. Cardiovasc Res 2005;67:69-76. 12. Kato K, Fujimaki T, Yoshida T, Oguri M, Yajima K, Hibino T, Murohara T. Impact of matrix metalloproteinase-2 levels on long- term outcome following pharmacological or electrical cardioversion in patients with atrial fibrillation. Europace 2009;11:332-337. 13. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial fibrillation follow-up investigation of rhythm management (AFFIRM) investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833. 14. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-988. 15. Bajpai A, Savelieva I, Camm AJ. Treatment of atrial fibrillation. Br Med Bull 2008;88:75-94. 16. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Heuzey JYL, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation- Executive Summary. JACC 2006;48:854-906. 17. Segal OR. Rate control for atrial fibrillation: one drug or two? Postgrad 2009;85:281-282. 176 Gholamreza Davoodi et al. 18. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial fibrillation and congestive heart failure investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-2677. 19. Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, Mahé I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006;166:719-728. 20. Betts TR. Is rate more important than rhythm in treating atrial fibrillation? Yes. BMJ 2009;339:b3173. 21. Freudenberger RS, Wilson AC, Kostis JB; AFFIRM investigators and committees. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM study). Am J Cardiol 2007;100:247-252. 22. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ; Rate control versus electrical cardioversion for persistent atrial fibrillation study group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840. 23. Rienstra M, Van Veldhuisen DJ, Crijns HJ, Van Gelder IC; RACE investigators. Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study. Eur Heart J 2007;28:741- 751. 24. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-pharmacological intervention in atrial fibrillation (PIAF): a randomized trial. Lancet 2000;356:1789-1794. 25. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U; STAF investigators. Randomized trial of rate- control versus rhythm-control in persistent atrial fibrillation: the strategies of treatment of atrial fibrillation (STAF) study. J Am Coll Cardiol 2003;41:1690-1696. 26. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk P; Investigators of the Polish how to treat chronic atrial fibrillation study. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish how to treat chronic atrial fibrillation (HOT CAFE) study. Chest 2004;126:476-486. 27. Guédon-Moreau L, Capucci A, Denjoy I, Morgan CC, Périer A, Leplège A, Kacet S. Impact of the control of symptomatic paroxysmal atrial fibrillation on health-related quality of life. Europace 2010;12:634-642. 28. Hemels ME, Wiesfeld AC, Van Veldhuisen DJ, Van den Berg MP, Van Gelder IC. Outcome of pharmacological rhythm control for new-onset persistent atrial fibrillation in patients with systolic heart failure: a comparison with patients with normal left ventricular function. Europace 2007;9:239-245. 29. Curtis AB, Seals AA, Safford RE, Slater W, Tullo NG, Vidaillet H, Wilber DJ, Slee A. Clinical factors associated with abandonment of a rate-control or a rhythm-control strategy for the management of atrial fibrillation in the AFFIRM study. Am Heart J 2005;149:304- 308. 30. Doyle JF, Ho KM. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc 2009;84:234-342. 31. Fitzgerald JD. Trials of discovery. Class III antiarrhythmic agents: serendipity or drug design? Dialog Cardiovasc Med 2004;9:243- 252. 32. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose ranging study. Eur Heart J 2003;24:1481-1487. 33. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagné P, Nattel S, Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. Canadian